Page last updated: 2024-12-08
lycoctonine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
lycoctonine: RN refers to (1alpha,6beta,14alpha,16beta)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 441746 |
| CHEMBL ID | 1242718 |
| CHEBI ID | 6590 |
| SCHEMBL ID | 2570467 |
| MeSH ID | M0247693 |
Synonyms (9)
| Synonym |
|---|
| lycoctonine |
| C08697 , |
| 26000-17-9 |
| chebi:6590 , |
| CHEMBL1242718 , |
| SCHEMBL2570467 |
| surecn2570467 |
| lycoctonine (royline) |
| (1s,2r,3r,4s,5r,6s,8r,9s,13s,16s,17r,18s)-11-ethyl-13-(hydroxymethyl)-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecane-8,9-diol |
Research Excerpts
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Treatment of a lycoctonine-type alkaloid acetyllycoctonine (4) with mCPBA at room temperature led to acetyllycoctonine N-oxide (5) as the major product together with other interesting compounds 6-12 as the minor products, which were derived from oxidation involving the nitrogen atom and Cope elimination as well as Polonovski-like fragmentation. " | ( mCPBA oxidation of acetyllycoctonine and its new products. Shen, XL; Wang, FP, 2005) | 0.98 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Mice were injected with several larkspur toxin-protein conjugates or adjuvant alone to determine whether the resulting immunological response altered animal susceptibility to methyllycaconitine, the major toxic larkspur alkaloid." | ( Evaluation of vaccination against methyllycaconitine toxicity in mice. Gardner, DR; James, LF; Lee, ST; Panter, KE; Pfister, JA; Schoch, TK; Stegelmeier, BL, 2003) | 0.32 |
| " Physicochemical-descriptor containing models, that are in a good agreement with the mode of toxic action exerted by the alkaloids studied, have also been identified and discussed." | ( A QSAR toxicity study of a series of alkaloids with the lycoctonine skeleton. Rasulev, BF; Turabekova, MA, 2004) | 0.57 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| diterpenoid | Any terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID510178 | Reduction of acetylcholine-induced muscle contraction in frog abdominal straight muscle | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | Aconitum and Delphinium alkaloids of curare-like activity. QSAR analysis and molecular docking of alkaloids into AChBP. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (16)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 17.03
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.03) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||